PharVision Advisers’s Ingredion INGR Stock Holding History

PharVision Advisers’s Portfolio INGR Stock Details INGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,871	Closed	-$257K	–	391
2024 Q4	$257K	Buy	+1,871	New	+$263K	0.22%	209

Other funds holding INGR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

YAM

Yacktman Asset Management Austin, Texas $7.5B AUM 22.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

PharVision Advisers's INGR Position: Q1 2025 in Review

PharVision Advisers sold out of Ingredion (INGR) in Q1 2025, closing a stake of 1,871 shares — an estimated $257K sold.

PharVision Advisers first reported a position in INGR in Q4 2024 and held it in 1 quarter. The position peaked at $257K in Q4 2024. 656 funds tracked by Wall St. Rank hold INGR as of Q1 2025.

PharVision Advisers reported no remaining Ingredion position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 1,871 Ingredion shares in Q1 2025, an estimated $257K.
PharVision Advisers first reported a position in Ingredion in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Ingredion position peaked at $257K in Q4 2024.
656 funds tracked by Wall St. Rank held Ingredion as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.